

Title (en)  
MANUFACTURING OF MULTI-DOSE INJECTION READY DENDRITIC CELL VACCINES AND COMBINATION THERAPY FOR BLOCKING HER2 AND HER3

Title (de)  
HERSTELLUNG VON GEBRAUCHSFERTIGEN MEHRFACHDOSISVAKZINEN AUS DENDRITISCHEN ZELLEN UND KOMBINATIONSTHERAPIE ZUR BLOCKIERUNG VON HER2 UND HER3

Title (fr)  
FABRICATION DE VACCINS À BASE DE CELLULES DENDRITIQUES MULTI-DOSES PRÊTS À ÊTRE INJECTÉS, ET POLYTHÉRAPIE POUR BLOQUER HER2 ET HER3

Publication  
**EP 3169774 A4 20180425 (EN)**

Application  
**EP 15822053 A 20150717**

Priority  
• US 201462025673 P 20140717  
• US 201462025685 P 20140717  
• US 201462029774 P 20140728  
• US 201562165445 P 20150522  
• US 2015041022 W 20150717

Abstract (en)  
[origin: WO2016011347A1] The present invention relates to an FDA- approved injectable multi-dose antigen pulsed dendritic cell (DC) vaccine. In one embodiment, the activated antigen- loaded DC vaccine comprises an initial immunizing dose and multiple "booster" doses. The invention also provides a method of blocking both HER-2 and HER-3 as a treatment in causing permanent tumor senescence in HER-2 expressing breast cancers.

IPC 8 full level  
**C12N 5/0784** (2010.01)

CPC (source: EP US)  
**A61K 38/191** (2013.01 - EP); **A61K 38/217** (2013.01 - EP); **A61K 39/001106** (2018.08 - US); **A61K 39/39558** (2013.01 - EP); **A61K 39/4615** (2023.05 - EP); **A61K 39/4622** (2023.05 - EP); **A61K 39/464406** (2023.05 - EP); **A61K 39/464499** (2023.05 - EP); **A61P 1/04** (2018.01 - EP); **A61P 1/18** (2018.01 - EP); **A61P 11/00** (2018.01 - EP); **A61P 13/08** (2018.01 - EP); **A61P 15/00** (2018.01 - EP); **A61P 17/00** (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 37/04** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07K 16/32** (2013.01 - EP); **C12N 5/0639** (2013.01 - EP); **A61K 2039/505** (2013.01 - EP); **A61K 2239/38** (2023.05 - EP)

C-Set (source: EP)  
1. **A61K 38/217 + A61K 2300/00**  
2. **A61K 38/191 + A61K 2300/00**  
3. **A61K 39/39558 + A61K 2300/00**

Citation (search report)  
• [XP] ELIZABETH FITZPATRICK ET AL: "Cryopreservation of activated DC1 makes large scale dendritic cell vaccines feasible in cancer therapy", CYTOTHERAPY, vol. 17, no. 6, 1 June 2015 (2015-06-01), GB, pages S22 - S23, XP055428214, ISSN: 1465-3249, DOI: 10.1016/j.jcyt.2015.03.381  
• [A] TAE HEE HAN ET AL: "Evaluation of 3 Clinical Dendritic Cell Maturation Protocols Containing Lipopolysaccharide and Interferon-[gamma]", JOURNAL OF IMMUNOTHERAPY, vol. 32, no. 4, 1 May 2009 (2009-05-01), pages 399 - 407, XP055156169, ISSN: 1524-9557, DOI: 10.1097/CJI.0b013e31819e1773

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2016011347 A1 20160121**; CN 107109365 A 20170829; EP 3169774 A2 20170524; EP 3169774 A4 20180425; EP 3714898 A1 20200930; JP 2017522328 A 20170810; JP 2020169178 A 20201015; JP 6967963 B2 20211117

DOCDB simple family (application)  
**US 2015040901 W 20150717**; CN 201580050434 A 20150717; EP 15822053 A 20150717; EP 20172302 A 20150717; JP 2017502877 A 20150717; JP 2020097202 A 20200603